Targeted delivery in primary and metastatic brain tumors: Summary report of the seventh annual meeting of the blood-brain barrier disruption consortium

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 1702-1709

  Doolittle, Nancy D ^a   Abrey, Lauren E ^b   Ferrari, Nicolay ^c   Hall, Walter A ^d   Laws, Edward R ^e   McLendon, Roger E ^f   Muldoon, Leslie L ^a   Peereboom, David ^g   Peterson, Darryl R ^h   Reynolds, C Patrick ⁱ   Senter, Peter ^j   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h The Chicago Medical College   (United States)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^j SEATTLE GENETICS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBODY CONJUGATE; BUTHIONINE SULFOXIMINE; CANCER VACCINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; HYBRID PROTEIN; INTERLEUKIN 4; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN; SODIUM THIOSULFATE; THIOL DERIVATIVE; TRANSFERRIN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CATARACT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE THERAPY; HUMAN; OTOTOXICITY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS;

EID: 0036278836     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Extent of resection as a prognostic variable in the treatment of gliomas
2. Current therapy for primary brain tumors
3. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
4. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis
5. O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
6. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy
7. Effects of continuous localized infusion of granulocytemacrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression
8. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas
9. Dendritic cells as immunologic adjuvants for the treatment of cancer
10. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
11. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
12. Temozolomide for treating brain metastases
13. Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy - A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group
14. Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study
15. A phase II study of temozolomide for patients with recurrent or progressive brain metastases
16. Temozolomide in patients with brain metastases from solid tumors. A Hellenic Cooperative Group Study
17. Temozolomide enhances radiation treatment efficacy in brain metastases: A randomized phase II study
18. Validation of the RTOG recursive partitioning analysis classification for brain metastases
19. Development and activities of the BR96-doxorubicin immunoconjugate
20. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
21. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)
22. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates
23. Characterization of a duocarmycin-DNA adduct-recognizing protein in cancer cells
24. Synthesis and evaluation of a series of C3-substituted CBI analogues of CC-1065 and the duocarmycins
25. Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor
26. Convection-enhanced delivery of macromolecules in the brain
27. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
28. Targeted toxin therapy for malignant astrocytoma
29. Importance of dose intensity in neuro-oncology clinical trials: Summary report of the sixth annual meeting of the blood-brain barrier disruption consortium
30. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
31. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival
32. Cognitive function, imaging studies, and survival in primary central nervous system lymphoma
33. Enhanced intra-arterial carboplatin-based chemotherapy delivery for relapsed primary CNS lymphoma (PCNSL)
34. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement
35. Increasing the therapeutic response rates to antitumor drugs by applying the basic principles of pharmacology
36. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS or intraocular lymphoma
37. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma
38. A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation in patients with newly diagnosed primary central nervous system lymphoma
39. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma
40. High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors
41. Treatment of intracranial nonger-minomatous germ-cell tumor by high dose chemotherapy and autologous stem cell rescue
42. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
43. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma
44. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines
45. Depletion of glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis
46. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression
47. Pilot study of buthionine sulfoximine (BSO) and melphalan (L-PAM) in children with recurrent neuroblastoma
48. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line
49. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide
50. N-(4-hydroxyphenyl) retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines
51. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism
52. Glutathione and glutathione delivery compounds
53. The genetic basis of resistance to cancer chemotherapy
54. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity
55. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants
56. First evidence of otoprotection against carboplatin- induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate
57. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors
58. Potential role of delayed high-dose sodium thiosulfate as protectant against carboplatin-based thrombocytopenia in patients with malignant brain tumors
59. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model
60. Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and future directions